Cargando…

Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay

Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramachandran, Preethi, Farag, Fady, Morcus, Rewais, Gotleib, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419528/
https://www.ncbi.nlm.nih.gov/pubmed/30850576
http://dx.doi.org/10.12659/AJCR.914575
_version_ 1783403962957824000
author Ramachandran, Preethi
Farag, Fady
Morcus, Rewais
Gotleib, Vladimir
author_facet Ramachandran, Preethi
Farag, Fady
Morcus, Rewais
Gotleib, Vladimir
author_sort Ramachandran, Preethi
collection PubMed
description Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced thrombocytopenia (aHIT) refers to a condition, in which antiplatelet factor-4 (PF4) antibodies activate platelets even in the absence of heparin (heparin independent platelet activation). This is a severe hypercoagulable state triggering massive thrombin storm needing additional therapies and aggressive anticoagulation apart from stopping heparin. Thrombocytopenia in these cases seems to be very severe and prolonged compared to classic HIT and poses additional clinical challenges in terms of anticoagulation management. Recently, direct oral anticoagulants (DOACs) seem to be an attractive option in the management of HIT as an alternative to vitamin K antagonists (VKA). CASE REPORT: We describe a case of a 55-year African American male who presented with pleuritic chest pain and was found to have worsening kidney disease. Clinical and electrocardiogram findings suggested uremic pericarditis, and dialysis was warranted. After 5 days of exposure to heparin flushes during dialysis, the patient developed thrombocytopenia, and subsequently HIT was diagnosed. Argatroban was started initially, however, his platelets count continued to drop, and he developed acute deep venous thrombosis of the right lower leg. IVIG (intravenous immunoglobulin) was started and his platelet count started to improve after several days. The patient was discharged on Eliquis and his platelet count returned to normal levels after 3 months. CONCLUSIONS: This case emphasizes the challenge managing HIT, a condition that has a high rate of complications. Several studies have reported platelet recovery with IV immunoglobulin when standard therapies fail. Recent evidence also supports the safety and efficacy of DOACs in offering a simplified way of managing these patients, especially in outpatient settings.
format Online
Article
Text
id pubmed-6419528
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64195282019-04-17 Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay Ramachandran, Preethi Farag, Fady Morcus, Rewais Gotleib, Vladimir Am J Case Rep Articles Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced thrombocytopenia (aHIT) refers to a condition, in which antiplatelet factor-4 (PF4) antibodies activate platelets even in the absence of heparin (heparin independent platelet activation). This is a severe hypercoagulable state triggering massive thrombin storm needing additional therapies and aggressive anticoagulation apart from stopping heparin. Thrombocytopenia in these cases seems to be very severe and prolonged compared to classic HIT and poses additional clinical challenges in terms of anticoagulation management. Recently, direct oral anticoagulants (DOACs) seem to be an attractive option in the management of HIT as an alternative to vitamin K antagonists (VKA). CASE REPORT: We describe a case of a 55-year African American male who presented with pleuritic chest pain and was found to have worsening kidney disease. Clinical and electrocardiogram findings suggested uremic pericarditis, and dialysis was warranted. After 5 days of exposure to heparin flushes during dialysis, the patient developed thrombocytopenia, and subsequently HIT was diagnosed. Argatroban was started initially, however, his platelets count continued to drop, and he developed acute deep venous thrombosis of the right lower leg. IVIG (intravenous immunoglobulin) was started and his platelet count started to improve after several days. The patient was discharged on Eliquis and his platelet count returned to normal levels after 3 months. CONCLUSIONS: This case emphasizes the challenge managing HIT, a condition that has a high rate of complications. Several studies have reported platelet recovery with IV immunoglobulin when standard therapies fail. Recent evidence also supports the safety and efficacy of DOACs in offering a simplified way of managing these patients, especially in outpatient settings. International Scientific Literature, Inc. 2019-03-09 /pmc/articles/PMC6419528/ /pubmed/30850576 http://dx.doi.org/10.12659/AJCR.914575 Text en © Am J Case Rep, 2019 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Ramachandran, Preethi
Farag, Fady
Morcus, Rewais
Gotleib, Vladimir
Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title_full Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title_fullStr Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title_full_unstemmed Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title_short Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
title_sort autoimmune heparin-induced thrombocytopenia: treatment obstacles and challenging length of stay
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419528/
https://www.ncbi.nlm.nih.gov/pubmed/30850576
http://dx.doi.org/10.12659/AJCR.914575
work_keys_str_mv AT ramachandranpreethi autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay
AT faragfady autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay
AT morcusrewais autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay
AT gotleibvladimir autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay